AP785A

AP785A - Novel taxoids, preparation thereof and pharmaceutical compositions containing same.

Info

Publication number: AP785A
Application number: APAP/P/1997/001090A
Authority: AP
Inventors: Herve Bouchard; Jean-Dominique Bourzat; Alain Commercon
Original assignee: Aventis Pharma Sa
Priority date: 1995-03-27
Filing date: 1996-03-25
Publication date: 1999-11-26
Also published as: MX9706568A; DK0817779T3; MA23823A1; PL188284B1; HUP9801201A3; MY121225A; DK0817780T3; RO115878B1; MX9706278A; PT817779E; AU5278196A; BR9607929A; EA199700269A1; ZA962399B; AU703278B2; AU711227B2; NO973923D0; BG63009B1; BG101917A; OA10513A

Abstract

Novel taxoids of general formula (I), the preparation thereof and pharmaceutical compositions containing them are described, wherein Z is a hydrogen atom or a radical of general formula (H), wherein RI is an optionally substituted benzoyl radical or a radical Rz-O-CO-where RZ is an optionally substituted phenyl, alkyl. alkcnyl. alkynyl. cycloalkyl. cycloalkenyl, bicycloallcyl. or heterocyclyl radical. Rj is an aromatic heterocyclic, alkyl, alkenyl, alkynyl. cycloalkyl. phenyl or naphthyl radical, R* is a substituted alkanoyloxy. alkenoyloxy, alkynoyloxy or cycloalkanoyloxy radical and Rj is an optionally substituted alkoxy radical or a cycloalkyloxy or cycloalkenyloxy radical. The novel products of general formula (I), where Z is a radical of general formula (II), have remarkable anti-tumour and anti-lcuk:mia properties. .

Description

NEW TAXOIDS, THEIR PREPARATION AND PHARMACEUTICAL

COMPOSITIONS CONTAINING THEM

The present invention relates to new taxoids of general formula:

(I) in which:

Z represents a hydrogen atom or a radical of general formula:

RjNH 0

R.

(Π)

OH

AP/P/ 97/01090 in which:

R_x represents a benzoyl radical optionally substituted with one or more identical or different atoms or radicals chosen from halogen atoms and alkyl radicals containing 1 to 4 carbon atoms, alkoxy radicals containing 1 to 4 carbon atoms or trifluoromethyi radicals, a thenoyl or furoyl radical or a radical R₂-0-C0- in which R₂ represents:

- an alkyl radical containing 1 to 8 carbon atoms, an alkenyl radical containing 2 to 8 carbon atoms, an alkynyl radical containing 3 to 8 carbon atoms, a )

AP. Ο Ο 7 β 5 cycloalkyl radical containing 3 to 6 carbon atoms, a cycloalkenyl radical containing 4 to 6 carbon atoms or a bicycloalkyl radical containing 7 to 10 carbon atoms, these radicals being optionally substituted with one or more substituents chosen from halogen atoms and hydroxyl radicals, alkoxy radicals containing 1 to 4 carbon atoms, dialkylamino radicals in which each alkyl portion contains 1 to 4 carbon atoms, piperidino or morpholino radicals, 1-piperazinyl radicals (optionally substituted at position 4 with an alkyl radical containing 1 to 4 carbon atoms or with a phenylalkyl radical in which the alkyl portion contains 1 to 4 carbon atoms), cycloalkyl radicals containing 3 to 6 carbon atoms, cycloalkenyl radicals containing 4 to 6 carbon atoms, phenyl radicals (optionally substituted with one or more atoms or radicals chosen from halogen atoms and alkyl radicals containing 1 to 4 carbon atoms or alkoxy radicals containing 1 to 4 carbon atoms), cyano or carboxyl radicals or alkoxycarbonyl radicals in which the alkyl portion contains 1 to 4 carbon atoms,

- a phenyl or a- or /S-naphthyl radical optionally substituted with one or more atoms or radicals chosen from halogen atoms and alkyl radicals containing 1 to 4 carbon atoms or alkoxy radicals containing 1 to 4 carbon atoms, or a 5-membered aromatic heterocyclic radical preferably chosen from furyl and thienyl

AP/P/ 9 7 / 0 1 0 9 0 radicals

AP. Ο Ο 7 8 5

- or a saturated heterocyclic radical containing 4 to 6 carbon atoms, optionally substituted with one or more alkyl radicals containing 1 to 4 carbon atoms,

R₃ represents an unbranched or branched alkyl radical containing 1 to 8 carbon atoms, an unbranched or branched alkenyl radical containing 2 to 8 carbon atoms, an unbranched or branched alkynyl radical containing 2 to 8 carbon atoms, a cycloalkyl radical containing 3 to 6 carbon atoms, a phenyl or a- or

0-naphthyl radical optionally substituted with one or more atoms or radicals chosen from halogen atoms and alkyl, alkenyl, alkynyl, aryl, aralkyl, alkoxy, alkylthio, aryloxy, arylthio, hydroxyl, hydroxyalkyl, mercapto, formyl, acyl, acylamino, aroylamino, alkoxycarbonylamino, amino, alkylamino, dialkylamino, carboxyl, alkoxycarbonyl, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, cyano, nitro and trifluoromethyl radicals, or a 5-membered aromatic heterocycle containing one or more identical or different hetero atoms chosen from nitrogen, oxygen and sulphur atoms and optionally substituted with one or more identical or different substituents chosen from halogen atoms and alkyl, aryl, amino, alkylamino, dialkylamino, alkoxycarbonylamino, acyl, arylcarbonyl, cyano, carboxyl, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl or alkoxycarbonyl radicals, on the understanding that, in the substituents of the phenyl, a- or 0-naphthyl and aromatic heterocyclic radicals, the alkyl radicals and

AP/P/ 97/010 9 0

AP.00785 the alkyl portions of the other radicals contain 1 to 4 carbon atoms, and that the alkenyl and alkynyl radicals contain 2 to 8 carbon atoms, and that the aryl radicals are phenyl or a- or 0-naph.thyl radicals,

R₄ represents an alkanoyloxy radical in which the alkanoyl portion contains 2 to 6 carbon atoms in an unbranched or branched chain, with the exception of an acetyl radical, an alkenoyloxy radical in which the alkenoyl portion contains 3 to 6 carbon atoms in an unbranched or branched chain or an alkynoyloxy radical in which the alkynoyl portion contains 3 to 6 carbon atoms in an unbranched or branched chain, these radicals being optionally substituted with one or more halogen atoms or with an alkoxy radical containing 1 to

4 carbon atoms or an alkylthio radical containing 1 to carbon atoms or with a carboxyl radical, an alkyloxycarbonyl radical in which the alkyl portion contains 1 to 4, carbon atoms, a cyano or carbamoyl radical or an N-alkylcarbamoyl or N,N-dialkylcarbamoyl

0 radical in which each alkyl portion contains 1 to 4 carbon atoms or, with the nitrogen atom to which it is linked, forms a saturated 5- or 6-membered heterocyclic radical optionally containing a second hetero atom chosen from oxygen, sulphur or nitrogen atoms, optionally substituted with an alkyl radical containing 1 to 4 carbon atoms or a phenyl radical or a phenylalkyl radical in which the alkyl portion contains 1 to 4 carbon atoms, or alternatively R₄ represents a

AP/P/ 9 7 / 0 1 0 9 0

AP. ο Ο 7 8 5 cycloalkanoyloxy radical in which the cycloalkanoyl portion contains 4 to 8 carbon atoms or a cycloalkenoyloxy radical in which the cyccloalkenoyl portion contains 4 to 8 carbon atoms, or alternatively R₄ represents a benzoyloxy radical or a heterocyclecarbonyloxy radical in which the heterocyclic portion represents a 5- or 6-membered aromatic heterocycle containing one or more hetero atoms chosen from oxygen, sulphur or nitrogen atoms,

R₅ represents an alkoxy radical containing 1 to 6 atoms this carbon an unbranched or branched chain, optionally substituted with an alkoxy radical

	containing	1	to	4	carbon
	containing	3	to	6	carbon
15	containing	3	to	6	carbon
	containing	3	to	6	carbon

radical containing 3 to 6 carbon atoms, these radicals being optionally substituted with one or more halogen atoms or with an alkoxy radical containing 1 to 4 carbon atoms, an alkylthio radical containing 1 to 4 carbon atoms or a carboxyl radical, an alkyloxycarbonyl radical in which the alkyl portion contains 1 to 4 carbon atoms, a cyano or carbamoyl radical or an N-alkylcarbamoyl or N,N-dialkylcarbamoyl radical in which each alkyl portion contains 1 to 4 carbon atoms or, with the nitrogen atom to which it is linked, forms a saturated 5- or 6-membered heterocyclic radical optionally containing a second hetero atom chosen from

AP/P/ 97 / 0 1 0 9 0

AP.00785 oxygen, sulphur or nitrogen atoms, optionally substituted with an alkyl radical containing 1 to 4 carbon atoms or a phenyl radical or a phenylalkyl radical in which the alkyl portion contains 1 to 4 carbon atoms .

Preferably, the aryl radicals which can be represented by R₃ are phenyl or a- or /S-naphthyl radicals optionally substituted with one or more atoms or radicals chosen from halogen atoms (fluorine, chlorine, bromine, iodine) and alkyl, alkenyl, alkynyl, aryl, arylalkyl, alkoxy, alkylthio, aryloxy, arylthio, hydroxyl, hydroxyalkyl, mercapto, formyl, acyl, acylamino, aroylamino, alkoxycarbonylamino, amino, alkylamino, dialkylamino, carboxyl, alkoxycarbonyl, carbamoyl, dialkylcarbancyl, cyano, nitro and trifluoromethyi radicals, on the understanding that the alkyl radicals and the alkyl portions of the other radicals contain 1 to 4 carbon atoms, that the alkenyl and alkynyl radicals contain 2 to 8 carbon atoms and that the aryl radicals are phenyl or a- or jS-naphthyl radicals.

Preferably, the heterocyclic radicals which can be represented by R₃ are 5-membered aromatic heterocyclic radicals containing one or more identical or different atoms chosen from nitrogen, oxygen and sulphur atoms, optionally substituted with one or more identical or different substituents chosen from halogen atoms (fluorine, chlorine, bromine, iodine) and alkyl

AP/P/ 9 7 / 0 1 0 9 0

AP.00785 ©

radicals containing 1 to 4 carbon atoms, aryl radicals containing 6 to 10 carbon atoms, alkoxy radicals containing 1 to 4 carbon atoms, aryloxy radicals containing 6 to 10 carbon atoms, amino radicals, alkylamino radicals containing 1 to 4 carbon atoms, dialkylamino radicals in which each alkyl portion contains 1 to 4 carbon atoms, acylamino radicals in which the acyl portion contains 1 to 4 carbon atoms, alkoxycarbonylamino radicals containing 1 to 4 carbon atoms, acyl radicals containing 1 to 4 carbon atoms, arylcarbonyl radicals in which the aryl portion contains 6 to 10 carbon atoms, cyano, carboxyl or carbamoyl radicals, alkylcarbamoyl radicals in which the alkyl portion contains 1 to 4 carbon atoms, dialkylcarbamoyl radicals in which each alkyl portion contains 1 to 4 carbon atoms or alkoxycarbonyl radicals in which the alkoxy portion contains 1 to 4 carbon atoms · z

Preferably, the radicals R₄ represents an alkyloxyacetoxy radical in which the alkyl portion contains 1 to 4 carbon atoms, a eyeloalkanoyloxy radical in which the cycloalkanoyl portion contains 4 to 8 carbon atoms, a cycloalkenoyloxy radical in which the cycloalkenoyl portion contains4 to 8 carbon atoms, a benzoyloxy radical or a heterocycle-carbonyloxy radical in which the heterocyclic portion represents a 5- or 6-membered aromatic heterocycle containing one or more hetero atoms chosen from oxygen, sulphur or

06010//6 /d/dV

AP.00785 nitrogen atoms, and R₅ represents an unbranched or branched alkoxy radical containing 1 to 6 carbon atoms, optionally substituted with a methoxy, ethoxy, methylthio, ethylthio, carboxyl, methoxycarbonyl, ethoxycarbonyl, cyano, carbamoyl, N-methylcarbamoyl,

N-ethyl carbamoyl, N,N-dimethylcarbamoyl, Ν,Ν-diethylcarbamoyl, N-pyrrolidinocarbonyl or N-piperidinocarbonyl radical.

More especially, the present invention relates to the products of general formula (I) in which Z represents a hydrogen atom or a radical of general formula (II) in which R_x represents a benzoyl radical or a radical R₂-O-CO- in which R₂ represents a tertbutyl radical and R₃ represents an alkyl radical containing 1 to 6 carbon atoms, an alkenyl radical containing 2 to 6 carbon atoms, a cycloalkyl radical containing 3 to 6 carbon atoms, a phenyl radical optionally substituted with one or more identical or different atoms or radicals chosen from halogen atoms (fluorine, chlorine) and alkyl (methyl) , alkoxy (methoxy) , dialkylamino (dimethylamino) , acylamino (acetylamino) , alkoxycarbonylamino (tertbutoxycarbonylamino) or trifluoromethyl radicals, or a

2- or 3-furyl, 2- or 3-thienyl or 2-, 4- or 5-thiazolyl radical, and R₄ represents an alkyloxyacetoxy radical in which the alkyl portion contains 1 to 4 carbon atoms, a cycloalkanoyloxy radical in which the cycloalkanoyl portion contains 4 to 6 carbon atoms or a

AP/P/ 9 7 / 0 1 0 9 0

AP. Ο Ο 7 8 5 pyridylcarbonyloxy radical, and R₅ represents an unbranched or branched alkyloxy radical containing 1 to carbon atoms.

Still more especially, the present invention relates to the products of general formula (I) in which Z represents a hydrogen atom or a radical of general formula (II) in which R_x represents a benzoyl radical or a radical R₂-O-CO- in which R₂ represents a tertbutyl radical and R₃ represents an isobutyl, isobutenyl, butenyl, cyclohexyl, phenyl, 2-furyl,

3-furyl, 2-thienyl, 3-thienyl, 2-thiazolyl, 4-thiazolyl or 5-thiazolyl radical, R₄ represents a methoxyacetoxy, cyclopropylcarbonyloxy, cyclopentylcarbonyloxy,

2-pyridylcarbonyloxy or 3-pyridylcarbonyloxy radical and R₅ represents a methoxy radical.

The products of general formula (I) in which Z represents a radical of general formula (II) display noteworthy antitumour and antileukaemic properties.

According to the present invention, the new products of'general formula (I) in which Z represents a radical of general formula (II) may be obtained by esterification of a product of general formula:

AP/P/ 9 7 / 0 1 0 9 0

ococ₆h₅

AP.ο Ο 7 8 5 in which R₄ and R₅ are defined as above, by means of an acid of general formula:

OH (IV)

.) in which R_x and R₃ are defined as above, and either R_grepresents a hydrogen atom and R₇ represents a group protecting the hydroxyl function, or R₆ and R₇ together form a saturated 5- or 6-membered heterocycle, or by means of a derivative of this acid, to obtain an ester of general formula:

(V)

AP/P/ 97 / 0 1 0 9 0 in which R_x, R₃, R₄, R₅, R₆ and R₇ are defined as above, followed by“replacement of the protective groups represented by R₇ and/or R_e and R₇ by hydrogen atoms.

The esterification by means of a product of general formula (XII) in which Χ_χ represents a hydroxyl radical may be performed in the presence of a condensing agent (carbodiimide, reactive carbonate) and an activating agent (aminopyridines) in an organic solvent (ether, ester, ketones, nitriles, aliphatic hydrocarbons, halogenated aliphatic hydrocarbons,

AP . Ο Ο 7 8 5 aromatic hydrocarbons) at a temperature of between -10 and 90°C.

The esterification may also be carried out using a product of general formula (XII) in which Χ_χrepresents a radical R₄-O-, working in the presence of an activating agent (aminopyridines) in an organic solvent (ethers, esters, ketones, nitriles, aliphatic hydrocarbons, halogenated aliphatic hydrocarbons, aromatic hydrocarbons) at a temperature of between 0 and 90°C.

The esterification may also be carried out using a product of general formula (XII) in which X_xrepresents a halogen atom, in. the presence of a base (tertiary aliphatic amine), working in an organic solvent (ethers, esters, ketones, nitriles, aliphatic hydrocarbons, halogenated aliphatic hydrocarbons, aromatic hydrocarbons) at a temperature of between 0 and 8 0 ⁰ C. ,

AP/P/ 97/01090

Preferably, R₆ represents a hydrogen atom and

R_? represents a group protecting the hydroxyl function, or alternatively R_s and R₇ together form a saturated 5or 6-membered heterocycle.

When R₆ represents a hydrogen atom, R₇preferably represents a methoxymethyl, 1-ethoxyethyl, benzyloxymethyl, trimethylsilyl, triethylsilyl,

0-trimethylsilylethoxymethyl, benzyloxycarbonyl or tetrahydropyranyl radical.

When R_s and R₇ together form a heterocycle

AP. Ο ο 7 8 5

the latter is preferably an oxazolidine ring optionally monosubstituted or gem-disubstituted at position 2.

Replacement of the protective groups R₇and/or R₆ and R₇ by hydrogen atoms may be performed, depending on their nature, in the following manner:

1) when R_e represents a hydrogen atom and R₇ represents a group protecting the hydroxyl function, replacement of the protective groups by hydrogen atoms is performed by means of an inorganic acid (hydrochloric acid, sulphuric acid, hydrofluoric.acid) or organic acid (acetic acid, methanesulphonic acid, trifluoromethanesulphonic acid, p-toluenesulphonic acid) used alone or mixed, working in an organic solvent chosen from alcohols, ethers, esters, aliphatic hydrocarbons, halogenated aliphatic hydrocarbons, aromatic hydrocarbons or nitriles at a temperature of between -10 and 60°C,

2) when R_s and R₇ together form a saturated 5- or 6membered heterocycle, and more especially an oxazolidine’ring of general formula:

06010//6 /d/dV

R_rN^O R_g R₉ (VI) in which is defined as above and R₈ and R_g, which may be identical or different, represent a hydrogen atom or an alkyl radical containing 1 to 4 carbon atoms, or an aralkyl radical in which the alkyl portion contains 1

AP. Ο Ο 7 8 5 ©

to 4 carbon atoms and the aryl portion preferably represents a phenyl radical optionally substituted with one or more alkoxy radicals containing 1 to 4 carbon atoms, or an aryl radical preferably representing a phenyl radical optionally substituted with one or more alkoxy radicals containing 1 to 4 carbon atoms, or alternatively R_g represents an alkoxy radical containing 1 to 4 carbon atoms or a trihalomethyl radical such as trichloromethyl or a phenyl radical substituted with a trihalomethyl radical such as trichloromethyl and R_g represents a hydrogen atom, or alternatively R_g and R₉, together with the carbon atom to which they are linked, form a 4- to 7-membered ring, replacement of the protective group formed by R₆ and R₇by hydrogen atoms may be performed, depending on the meanings of R_x, R_g and R_g, in the following manner:

a) when R_x represents a tert-butoxycarbonyl radical and R_g and R_g, which may be identical or different, represent an alkyl radical or an aralkyl (benzyl) or “aryl (phenyl) radical, or alternatively R_grepresents a trihalomethyl radical or a phenyl radical substituted with a trihalomethyl radical and R_grepresents a hydrogen atom, or alternatively R_g and R_gtogether form a 4- to 7-membered ring, treatment of the ester of general formula (V) with an inorganic or organic acid, where appropriate in an organic solvent such as an alcohol, yields the product of general

AP/P/ 9 7 / 0 1 0 9 0 formula:

AP . Ο θ 7 8 5 (VII)

in which R₃, R₄ and R₅ are defined as above, which is acylated by means of benzoyl chloride in which the phenyl ring is optionally substituted or by means of y thenoyl chloride, of furoyl chloride or of a product of general formula:

Ro-O-CO-X (VIII) in which R₂ Is defined as above and X represents a halogen atom (fluorine, chlorine) or a residue -0-R₂ or -O-CO-O-R,, to obtair. product of general formula (I) in which Z represents a radical of general formula (II) ·

Preferably, the product of general formula (V) is treated with formic acid at a temperature in the region of 20°C to yield the product of general formula (VII).

Preferably, the acylation of the product of general formula (VII) by means of a benzoyl chloride in which the phenyl radical is optionally substituted or by means of thenoyl chloride, of furoyl chloride or of a product of general formula (VIII) is performed in an inert organic solvent chosen from esters such as ethyl acetate, isopropyl acetate or n-butyl acetate and

AP/P/ 97/01090

AP. Ο Ο 7 8 5

halogenated aliphatic hydrocarbons such as dichloromethane or 1,2-dichloroethane, in the presence of an inorganic base such as sodium bicarbonate or an organic base such as triethylamine. The reaction is performed at a temperature of between 0 and 50°C, and preferably in the region of 2 0 °C.

b) when R_x represents an optionally substituted benzoyl radical, a thenoyl or furoyl radical or a radical R₂O-CO- in which R₂ is defined as above, R₈ represents a hydrogen atom or an alkoxy radical containing 1 to 4 carbon atoms or a phenyl radical substituted with one or more alkoxy radicals containing 1 to 4 carbon atoms and R₉ represents a hydrogen atom, replacement of the protective group formed by R₆ and R₇ by hydrogen atoms is performed in the presence of an inorganic acid (hydrochloric acid, sulphuric acid) or organic acid (acetic acid, methanesulphonic acid, trifluoromethanesulphonic acid, /

p-toluenesulphonic acid) used alone or mixed in a stoichiometric or catalytic amount, working in an organic solvent chosen from alcohols, ethers, esters, aliphatic hydrocarbons, halogenated aliphatic hydrocarbons and aromatic hydrocarbons at a temperature of between -10 and 60°C, and preferably between 15 and

30°C.

AP/P/ 97 / 0 1 0 90

According to the invention, the products of general formula (III), that is to say the products of general formula (I) in which Z represents a hydrogen

AP. Ο Ο 7 8 5 atom and R₄ and R₅ are defined as above, may be obtained from 10-deacetylbaccatin III of formula:

(ix) .0 j

It can be especially advantageous to protect the hydroxyl functions at the positions 7 and 13 selectively, for example in the form of a silyl diether which may be obtained by the action of a silyl halide of general formula:

(R)₃-Si-Hal (X) in which the symbols P, which may be identical or different, represent an alkyl radical containing 1 to 4 carbon atoms, optionally substituted with a phenyl radical, or a phenyl radical, on 10-deacetylbaccatin /

III, to obtain a product of general formula:

(XI)

AP/P/ 9 7 / 0 1 0 90 in which R is defined as above, followed by the action 15 of a product of general formula:

R'₄-X_x (XII)

AP.ο Ο 7 8 5 in which R'₄ is such that R'₄-O- is identical to R₄defined as above but cannot represent a hydrogen atom or a hydroxyl radical, and Χ_χ represents a halogen atom, to obtain a product of general formula:

(XIII) in which R and R₄ are defined as above, the silyl protective groups of which are replaced by hydrogen atoms to obtain a product of general formula:

(XIV)

AP/P/ 97 / 0 1 0 9 0 in which R₄~is defined as above, which is etherified selectively at position 7 by the action of a product of general formula:

R'₅-X₂ (XV) in which is such that R'₅-O- is identical to R₅ defined as above and X₂ represents [lacuna] halogen atom or a sulphuric or sulphonic ester residue, to give the product of general formula (III).

Generally, the action of a silyl derivative

AP.00785 of general formula (X) on 10-deacetylbaccatin III is performed in pyridine or triethylamine, where appropriate in the presence of an organic solvent such as an aromatic hydrocarbon, for instance benzene, toluene or xylenes, at a temperature between 0°C and the refluxing temperature of the reaction mixture.

Generally, the action of a product of general formula (XII) on a product of general formula (XI) is performed, after metalation of the hydroxyl function at position 10 by means of an alkali metal hydride such as sodium hydride, an alkali metal amide such as lithium amide or an alkali metal alkylide such as butyllithium, working in an organic solvent such as dimethylformamide or tetrahydrofuran at a temperature of between 0 and

Generally, the replacement of the silyl protective groups of the product of general formula (XIII) by hydrogen atoms is performed by means of an z

acid such as hydrofluoric acid or trifluoroacetic acid in the presence of a base such as triethylamine or pyridine optionally substituted with one or more alkyl radicals containing 1 to 4 carbon atoms, the base optionally being combined with an inert organic solvent such as a nitrile, for instance acetonitrile, or a halogenated aliphatic hydrocarbon such as dichloromethane at a temperature of between 0 and 80°C.

Generally, the action of a product of general formula (XV) on a product of general formula (XIV) is

AP/P/ 97/01090

AP. Ο Ο 7 8 5 performed under the conditions described above for the action of a product of general formula (XII) on a product of general formula (XI).

According to the invention, the products of 5 general formula (I) in which Z represents a radical of general formula (II) , and R₄ and R₅ are defined as above may be obtained from a product of general formula:

in which R_x, R,, R_g and R₇ are defined as above, by silylation at position 7 by means of a product of general formula (X), to obtain a product of general formula:

(XVII)

AP/P/ 97/01090 in which R, Rj, R₃, R_g and R₇ are defined as above, which is functionalized at position 10 by means of a product of general formula (XII) to give a product of general formula:

ΑΡ.00785 (XVIII)

in which R, R_1# R₃, R₄, Rg and R₇ are defined as above, the silyl protective group of which is replaced by a hydrogen atom to give a product of general formula:

(xix) which, by the action of a product of general formula 5 (XV), yields the product of general formula (V), the protective groups of which are replaced by hydrogen z

atoms to give a product of general formula (I) in which Z represents a radical of general formula (II).

The reactions used for silylation, functionalization and replacement of the protective groups by hydrogen atoms are performed under conditions similar to those described above.

The products of general formula (XVI) may be obtained under the conditions described in European

Patent EP 0,336,841 and International Applications

PCT WO 92/09589 and WO 94/07878, or from the products

AP/P/ 9 7 / 0 1 0 9 0

AP.00785 of general formula

in which R_x and R₃ are defined as known methods for protecting the the side chain without affecting above, according to hydroxyl function of the remainder of the molecule.

According to the invention, the products Of general formula (I) in which Z represents a hydrogen atom or a radical of general formula (II) may be obtained by the action of activated Raney nickel, in the presence of an aliphatic alcohol containing 1 to 3 carbon atoms, on a product of general formula:

AP/P/ 97 / 0 1 0 90 in which R₄ is defined as above and R' and R, which may be identical or different, represent a hydrogen

AP.00785 an alkyl radical containing 1 to 6 carbon atoms, an alkenyl radical containing 2 to 6 carbon atoms, an alkynyl radical containing 2 to 6 carbon atoms, a cycloalkyl radical containing 3 to 6 carbon atoms or a cycloalkenyl radical containing 3 to 6 carbon atoms, or alternatively R' and R, together with the carbon atom to which they are linked, form a cycloakyl radical containing 3 to 6 carbon atoms or a cycloalkenyl radical containing 4 to 6 carbon atoms, and Z₃ represents a hydrogen atom or a radical of general formula:

(XXII) in which R₃ and R₃ are defined as above, and either R_srepresents a hydrogen atom and R₇ represents a group protecting the hydroxyl function, or R₆ and R₇ together form a saturated 5- or 6-membered heterocycle, and R₄ is defined as above, to obtain a product of general formula:

AP/P/ 97 / 0 1 0 9 0

AP. Ο Ο 7 8 5

followed, when Ζ_χ represents a radical of general formula (XXII) , that is to say when the product of general formula (XXIII) is identical to the product of general formula (V), by replacement of the protective groups represented by R_s and/or R_s and R₇ by hydrogen atoms under the conditions described above.

Generally, the action of activated Raney nickel in the presence of the aliphatic alcohol is performed at a temperature of between -10 and 60°C.

According to the invention, the product of general formula (XXI) in which Ζ_χ and R₄ are defined as above may be obtained by the action of a dialkyl sulphoxide of general formula:

R' R'

R 1 J—R ^(XXIV) ^SO in which R' and R are defined as above, on a product of general formula (XIX).

Generally, the reaction of the sulphoxide of general formula (XXIV), preferably dimethyl sulphoxide, with the product of general formula (XIX) is performed in the presence of a mixture of acetic acid and acetic anhydride or a derivative of acetic acid such as a haloacetic acid at a temperature of between 0 and 50°C, and preferably in the region of 25°C.

According to the invention, the products of general formula (I) in which Z represents a radical of general formula (II) may be obtained by the action of a

AP/P/97 / 0 1 0 90

AP.00785 product of general formula (XII) on a product of general formula:

(XXV) in which R_x, R₃, R₅, R_g and R₇ are defined as above, working under the conditions described for the action of a product of general formula (XII) on a product of general formula (XI), followed by replacement of the protective groups represented by R₇ or R_g and R₇ by hydrogen atoms under the conditions described above.

The product of general formula (XXV) may be obtained by the action of a zinc halide such as zinc iodide or hydrazine on a product of general formula:

t·,

(XXVI)

AP/P/ 97/01090 in which R_lz R₃, R₅, R_g and R₇ are defined as above.

Generally, the reaction is performed working in an aliphatic alcohol containing 1 to 4 carbon atoms, 15 such as methanol or ethanol, at a temperature of between 0 and 50°C.

AP. Ο Ο 7 8 5

The product of general formula (XXVI) may be obtained by the action of activated Raney nickel in the presence of an aliphatic alcohol containing 1 to 3 carbon atoms on a product of general formula:

(XXVII) in which R-,, R₃, R_s, R₇, R' and R are defined as above, working under the conditions described above for the preparation of a product of general formula (I) from a product of general formula (XXI).

The product of general formula (XXVII) may be obtained by the action of a sulphoxide of general

AP/P/ 9 7 / 0 1 0 90

(XXVHD in which R_x, R₃, R_g and R₇ are defined as above, working under the conditions described above for the action of a sulphoxide of general formula (XXIV) on a product of

AP.00785 general formula (XIX).

The product of general formula (XXVIII) maybe obtained from a product of general formula:

(XXIX) in which R_x, R₃, R_e and R₇ are defined as above, working 5 under the conditions described above for replacing the sylil groups of the product of general formula (XIII) by hydrogen atoms .

The product of general formula (XXIX) may be prepared under the conditions described in

International Application PCT WO 95/11241.

The new products of general formula (I) obtained by carrying out the processes according to the invention may be purified according to known methods such as crystallization or chromatography.

The products of general formula (I) in which

Z represents a radical of general formula (II) display noteworthy biological properties.

In vitro, measurement of the biological activity is performed on tubulin extracted from pig's brain by the method of M.L. Shelanski et al., Proc.

Natl. Acad. Sci. USA, 70, 765-768 (1973). Study of the depolymerization of microtubules to tubulin is

6 0 I 0 / L 6 /d/dV

AP. Ο Ο 7 8 5 performed according to the method of G. Chauviere et al., C.R. Acad. Sci., 293, series II, 501-503 (1981). In this study, the products of general formula (I) in which Z represents a radical of general formula (II) were shown to be at least as active as taxol and

Taxotere.

In vivo, the products of general formula (I) in which Z represents a radical of general formula (II) were shown to be active in mice grafted with B16 melanoma at doses of between 1 and 10 mg/kg administered intraperitoneally, as well as on other liquid or solid tumours.

The new products have antitumour properties, and more especially activity against tumours which are resistant to Taxol® or to Taxotere®. Such tumours comprise colon tumours which have a high expression of the mdr 1 gene (multiple drug resistance gene) . Multiple drug resistance is a customary term relating to the resistance of a tumour to different products having different structures and mechanisms of action. Taxoids are generally known to be strongly recognized by experimental tumours such as P388/DOX, a cell line selected for its resistance to doxorubicin (DOX) which expresses mdr 1.

The examples which follow illustrate the present invention.

AP/P/ 9 7 / 0 1 0 90

EXAMPLE 1

243 mg of 4a-acetoxy-2a-benzoyloxy-5/5,20AP. Ο ο 7 8 5

©' epoxy-10-hydroxy-70-methoxy-9-oxo-100-(3 pyridylcarbonyl)oxy-11-taxen-13a-yl (2R,4S,5R)-3-tertbutoxycarbonyl-2 - (4-methoxyphenyl) -4-phenyl-l,3 oxazolidine-5-carboxylate are dissolved in 4.5 cm³ of a

0.1 N ethanolic solution of hydrochloric acid containing 1% of water. The solution thereby obtained is stirred for 3 hours at a temperature in the region of 20°C and 25 cm³ of diehloromethane are then added.

The organic phase is separated after settling has taken place and washed successively wxth 2 x 10 cm of saturated aqueous sodium hydrogen carbonate solution, dried over magnesium sulphate, filtered and 'Oncentrated to dryness under reduced pressure (2.7 kPa) at 40°C. 290 mg of a white foam are obtained, which is purified by chromatography on silica gel deposited on plates [(gel thickness 1 mm, plates 20 x 20 cm, eluent: dichloromethane/methanol (95:5 by volume)] in 80-mg fractions (4 plates). After localization with UV rays of the zone corresponding to the adsorbed product sought, this zone is scraped off and the silica collected is washed on sintered glass with 10 x 10 cm³ of ethyl acetate. The filtrates are combined and concentrated to dryness under reduced pressure (2.7 kPa) at 20°C. A white foam is obtained, which is repurified according to the same technique [(2 plates: 20 x 20 χ 1 mm; eluent: diehloromethane/ methanol (95:5 by volume)]. 132 mg of 4a-acetoxy-2abenz oy loxy - 5 0, 2 0 - epoxy -10 - hydroxy - 7 0 -me thoxy - 9 - oxo -10 0 AP/P/ 97 / 0 1 0 90

AP.00785

(3-pyridylcarbonyl)oxy-11-taxen-13a-yl (2R,3S)-3-tertbutoxycarbonylamino- 2 -hydroxy- 3 -phenylpropionate are thereby obtained in the form of a white foam, the characteristics of which are as follows:

- optical rotation: [a]₂₀ = -34 (^c = θ·5; methanol).

- ¹H NMR spectrum (300 MHz; CDC1₃: chemical shifts δ in ppm; coupling constants J in Hz): 1.30 (s, 3H: -CH₃ at position 16 or 17); 1.35 I(s, 12H: -C(CH₃)₃ and -CH₃ at position 16 or 17]; 1.75 (s, 3H: -CH₃) ; 1.82 and 2.77 (2 mts, 1H each: -CH₂- at position 6); 1.97 (s, 3H:

-CH₃); 2.35 (d, J = 9, 2H: -CH₂- at position 14); 2.39 (s, 3H: -COCH₃); 3.38 (d, J = 5, 1H: -OH at position 2'); 3.42 (s, 3H: -OCH₃) ; 3.88 (d, J = 7.5, 1H: -H at position 3); 3.96 (dd, J = 11 and 7.5, 1H: -H at position 7); 4.18 and 4.32 (2d, J = 8.5, 1H each: -CH₂at position 20); 4.64 (mt, 1H: -H at position 2'); 4.98 (broad d, J = 10, 1H: -H at position 5); 5.28 (broad d',

J = 10, 1H: -H at position 3'); 5.39 (d, J = 10, 1H:

-CONH-); 5.70 (d, J = 7.5, 1H: -H at position 2); 6.22 (broad t, J = 9, 1H: -H at position 13); 6.69 (s, 1H:

-H at position 10); from 7.25 to 7.45 (mt, 5H: -C_gH₅ at position 3'); 7.44 [(dd, J = 8.5 and 6, 1H: -OCOC₅H₄N(-H at position 5)]; 7.50 [(dd, J = 7.5, 2H: -OCOC_gH₅(-H at position 3 and H at position 5)]; 7.62 [(t, J = 7.5,

1H: -OCOC_eH₅{-H at position 4)]; 8.12 [ (d, J = 7.5, 2H:

-OCOC₅H₅(-H at position 2 and -H at position 6)]; 8.35 [(dt, J = 8.5 and 1, 1H: -OCOC₅H₄N(-H at position 4)]; 8.82 (dd, J = 6 and 1, 1H: -OCOC₅H₄N(-H at position 6)];

6 0 I- 0 / Z 6 /d/dV

AP.00785

9.32 (d, J = 1, IH: -OCOC₅H₄N(-H at position 2)].

4a-Acetoxy-2a-benzoyloxy-5/S, 2 0-epoxy-1/3hy dr oxy-7/3-methoxy-9-oxo-10/3- (3-pyridylcarbonyl) oxy-11taxen-13a-yl (2R, 4S, 5R) - 3 - tert-butoxycarbonyl-2 - (4 5 methoxyphenyl) -4-phenyl-l, 3-oxazolidine-5-carboxylate may be prepared in the following manner:

290 mg of 4a-acetoxy-2a-benzoyloxy-5/S,20epoxy- 1/3,10/3-dihydroxy-7/3-methoxy-9-oxo-11-taxen-13a-yl (2R,4S,5R)-3-tert-butyoxycarbonyl-2-(4-methoxyphenyl)10 4-phenyl-l,3-oxazolidine-5-carboxylate, 18.5 mg of

4-(dimethylamino)pyridine, 0.5 g of 4 A molecular sieve and 112 mg cf N,Ν'-dicyclohexylcarbodiimide are added at a temperature in the region of 20°C to a solution, kept stirring under an argon atmosphere, of 46 mg of

3-pyridinecarboxylic acid in 25 cm³ of anhydrous ethyl acetate. The reaction mixture is kept stirring for 16 hours at a temperature in the region of 20°C, 46 mg of 2-pyridinecarboxylic acid, 18.5 mg of

4-(dimethylamino)pyridine, 0.5 g of 4 A molecular sieve and 112 mg of N,Ν'-dicyclohexylcarbodiimide are then added and the mixture is again kept stirring for 24 hours, this cycle then being repeated twice more.

The reaction mixture is filtered through sintered glass lined with Celite. The sintered glass is washed with

2 times 50 cm³ of ethyl acetate, and the filtrates are combined, washed successively with 2 times 10 cm³ of saturated aqueous sodium hydrogen carbonate solution and with 6 times 20 cm³ of distilled water, dried over

AP/P/ 97 / 0 1 0 9«

AP . Ο Ο 7 θ 5 magnesium sulphate, filtered and concentrated to dryness under reduced pressure (2.7 kPa) at 40°C.

298 mg of 4a-acetoxy-2a-benzoyloxy-5/3,2O-epoxy-10hydroxy - 7 β - me thoxy - 9 - oxo -10 /3 - (3- py r idyl carbonyl) oxy -115 taxen-13a-yl (2R, 4S, 5R)-3 - tert-butoxycarbonyl-2 - (4methoxyphenyl) - 4 -phenyl -1,3 - oxazolidine - 5 - carboxylate are thereby obtained in the form of a white foam.

4a-Acetoxy-2o;-benzoyloxy-5jS, 20-epoxy-ljS, 10/3dihydroxy-7/3-methoxy-9-oxo-ll-tazen-13a-yl (2R,4S,5R) 10 3-tert-butoxycarbonyl-2- (4-methoxyphenyl) -4-phenyl-l,3oxazolidine-5-carboxylate may be prepared in the following manner

0.263 cm³ of hydrazine monohydrate is added dropwise and at a temperature in the region of 20°C to a solution, kept stirring under an argon atmosphere, of 150 mg of 4a-acetoxy-2o!-benzoyloxy-5£,20-epoxy-l/3hydroxy-7/S-methoxy-10jS-methoxyacetoxy-9-oxo-ll-taxen- . 13a-yl (2R,4S,5R)-3-tert-butoxycarbonyl-2-(4me thoxypheny 1 )-4- phenyl -1,3 - oxa ζ ο 1 idine - 5 - carboxy 1 a t e in 4 cm³ of ...anhydrous ethanol. The reaction medium is kept stirring for 1 hour at a temperature in the region of 20°C and then poured into a mixture of 100 cm³ of ethyl acetate and 50 cm³ of distilled water. The organic phase is separated after settling has taken place and the aqueous phase is re-extracted with times 50 cm³ of ethyl acetate. The organic phases are combined, washed with 4 times 50 cm³ of distilled water, dried over magnesium sulphate, filtered and

AP/P/ 9 7 / 0 1 0 90

AP . ο Ο 7 8 5 concentrated to dryness under reduced pressure (2.7 kPa) at 40°C. 180 mg of a white foam are obtained, which is purified by chromatography on silica gel deposited on plates [(gel thickness 1 mm, plates

20 x 20 cm, eluent: dichloromethane/methanol (90:10 by volume)] in 90 mg fractions (2 plates). After localization with UV rays of the zone corresponding to the adsorbed product sought, this zone is scraped off and the silica collected is washed on sintered glass with 10 times 10 cm³ of ethyl acetate. The filtrates are combined and concentrated to dryness under reduced pressure (2.7 kPa) at 40°C. 113 mg of 4a-acetoxy-2abenz oy 1 oxy - 5 β, 2 0 - epoxy -1/3,10/3 - dihydroxy -7/3 -me thoxy - 9 oxo-11-taxen-13a-yl (2R,4S,5R)-3-tert-butoxycarbonyl-215 (4-methoxyphenyl)-4-phenyl-l,3-oxazolidine-5carboxylate are thereby obtained in the form of a white foam.

4a-Acetoxy-2a-benzoyloxy-5/S, 20-epoxy-1/3hydroxy- 7 /3-me thoxy-10/3 -me thoxy ace toxy- 9 - oxo-11 - taxen20 13a-yl (2R, 4S,5R)-3-tert-butoxycarbonyl-2-(4methoxyphenyl)4-phenyl-l,3-oxazolidine-5-carboxylate may be prepared in the following manner:

100 cm³ of an ethanolic suspension of activated nickel prepared by Raney's method (obtained from 80 cm³ of the approximately 50% commercial aqueous suspension, by successive washing to a pH in the region of 7 with 15 times 100 cm³ of distilled water and with 4 times 150 cm³ of ethanol) are added at a temperature

AP/P/ 97 / 0 1 0 9 0

AP . Ο Ο Ί 85 in the region of 20°C to a solution, kept stirring under an argon atmosphere, of 1.041 g of 4a-acetoxy-2abenz oy loxy - 5 β, 2 0 - epoxy - 1β - hydroxy -10 β - me thoxyac e t oxy 7/3-methylthiomethoxy- 9-oxo-11-taxen-13o;-yl (2R, 4S, 5R) 5 3-tert-butoxycarbonyl-2 - (4-methoxyphenyl) -4-phenyl-l,3 oxazolidine-5-carboxylate in 100 cm³ of anhydrous ethanol. The reaction mixture is kept stirring for 7 days at a temperature in the region of 2 0°C and is then filtered through sintered glass. The sintered glass is washed with 3 times 100 cm³ of ethanol and the filtrates are combined and concentrated to dryness under reduced pressure (2.7 kPa) at 40°C. 821 mg of a white foam are obtained, which is purified by chromatography on 75 g of silica (0.063-0.2 mm)

If contained in a column 2.5 cm in diameter [eluent: dichloromethane/ethyl acetate (90:10 by volume)], collecting 5-cm³ fractions. The fractions containing only the product sought are pooled and concentrated to dryness under reduced pressure (2.7 kPa) at 40°C.

228 mg of 4a-acetoxy-2a-benzoyloxy-5/5, 20-epoxy-l/Shy dr oxy -7 β- me t hoxy -10 β - me thoxyac e t oxy - 9-oxo-11-1 axen 13or-yl (2R,4S, 5R) -3-ter t-butoxycarbonyl-2- (4me thoxyphenyl )-4 -phenyl -1,3 - oxazolidine - 5 - carboxylate are thereby obtained in the form of a white foam.

4a-Acetoxy-2/5-benzoyloxy-5/5,2 0 -epoxy- 1/5hy dr oxy -10 β - me thoxyac e t oxy -7 β- me t hy 11 hi ome thoxy - 9 - oxo 11-taxen-13a-yl (2R,4S,5R)-3-tert-butoxycarbonyl-2-(4methoxyphenyl) - 4 -phenyl -1,3 - oxazolidine - 5 - carboxylate

AP/P/ 97 / 0 1 0 90

AP. Ο Ο 7 8 5

may be prepared in the following manner:

3.35 cm³ of acetic acid and 11.5 cm³ of acetic anhydride are added at a temperature in the region of 2 0°C to a solution, kept stirring under an argon atmosphere, of 5 g of 4a-acetoxy-2/S-benzoyloxy-5/8, 20epoxy- 1β, 7/8-dihydroxy- 10/S-methoxyacet oxy- 9 - oxo-11 taxen-13a-yl (2R,4S,5R)-3-tert-butoxycarbonyl-2-(4me thoxypheny 1) - 4 - phenyl -1,3 - oxazolidine- 5 - carboxylate in 165 cm³ of anhydrous dimethyl sulphoxide. The reaction mixture is kept stirring for 3 days at a temperature in the region of 20 °C and is then poured into 500 cm³ of dichioromethane. 100 cm³ of saturated aqueous potassium carbonate solution are then added with efficient stirring to a pH in the region of 7.

After stirring forr 10 minutes, the organic phase is separated after settling has taken place and the aqueous phase is re-extracted with 2 times 250 cm³ of dichioromethane. The organic phases are combined, washed with 3 times 100 cm³ of distilled water, dried over magnesium sulphate, filtered and concentrated to dryness under reduced pressure (2.7 kPa) at 40°C. 9.5 g of a pale yellow oil are obtained, which is purified by chromatography on 250 g of silica (0.063-0.4 mm) contained in a column 3 cm in diameter [eluent:

dichloromethane/methanol (99:1 by volume)], collecting 50-cm³ fractions. The fractions containing only the product sought are pooled and concentrated to dryness under reduced pressure (2.7 kPa) at 40°C. 3.01 g of

AP/P/ 9 7 / 0 1 0 9 0

AP. 0 0 7 8 5

4a-acetoxy-2/S-benzoyloxy-5/3, 20 -epoxy -1/3-hydroxy-10/3me thoxy ac e t oxy - 7 /3 - me thyl thi ome thoxy - 9 - oxo -11 -1 axen -13 a yl (2R,4S,5R)-3-tert-butoxycarbonyl-2-(4me thoxypheny 1 )-4- phenyl -1,3 - oxaz ο 1 i dine - 5 - carboxyl ate are thereby obtained in the form of a white foam.

4a-Acetoxy-2/5-benxoyloxy-5/8,20-epoxy-l/S,7/3dihydr oxy -10 β - me thoxyac e t oxy - 9 - oxo -11 -1 axen -13 a - yl (2R,4S,5R) -3-tert-butoxycarbonyl-2- (4-methoxyphenyl) -4phenyl-1,3-oxazolidine-5-carboxylate may be prepared in the following manner:

220 cm³ of triethylamine/hydrofluoric acid (mole ratio 1:3) complex are added dropwise at a temperature in the region of 0°C to a solution, kept stirring under an argon atmosphere, of 20 g of 4a-acetoxy-2a-bensoyloxy-5/S, 20-epoxy-7,5t r i e thy 1 s i lyl oxy -1 β - hydroxy -10 β - me thoxyac e t oxy - 9 - oxo ll-taxen-13a-yl (2R,4S,5R)-3 - tert-butoxycarbonyl-2 - (4methoxyphenyl) - 4 -phenyl -1,3 - oxazolidine- 5 - carboxylate in 200 cm³ of anhydrous dichioromethane. The reaction mixture is then warmed to a temperature in the region of 20°C, maintained for 3 hours at this temperature and poured into 4 litres of saturated aqueous sodium hydrogen carbonate solution. The pH of the reaction medium thus being brought to around 7. After stirring for 10 minutes, the organic phase is separated after settling has taken place and the aqueous phase is extracted with 2 times 100 cm³ of dichioromethane. The organic phases are combined, washed with 100 cm³ of

6 0 1 0 / L 6 /d/dV

AP . Ο Ο 7 8 5 j' distilled water, dried over magnesium sulphate, filtered and concentrated to dryness under reduced pressure (2.7 kPa) at 40°C. 17.4 g of 4a-acetoxy-2abenzoyloxy-50,2O-epoxy-10,70-dihydroxy-1005 methoxyacetoxy-9-oxo-ll-taxen-13oi-yl (2R, 4S, 5R) - 3 - tertbutoxycarbonyl-2 - (4-methoxyphenyl) -4-phenyl-l, 3oxazolidine-5-carboxylate are thereby obtained in the form of a white foam.

4a-Acetoxy-2a-benzoyloxy-50, 2 0 - epoxy-7010 triethyls ilyloxy- 10-hydroxy-lO0-methoxyacetoxy- 9 -oxo11-taxen-13a-yl (2R, 4S,5R)-3-tert-butoxycarbonyl-2-(4methoxyphenyl) -4-phenyl-l, 3 -oxazolidine-5-carboxylate may he prepared under the conditions described in International Application PCT WO 95/11241.

EXAMPLE 2

Working as in Example 1, but starting from 210 mg of 4a-acetoxy-2a-benzoyloxy-50,20-epoxy-10hydroxy-70-methoxy-9-oxo-lO0-(2-pyridylcarbonyl)oxy-11taxen-13a-yl (2R, 4S,5R)-3-tert-butoxycarbonyl-2-(420 methoxyphenyl) -4-phenyl-l, 3-oxazolidine-5-carboxylate, 145 mg of 4a-acetoxy-2a-benzoyloxy-50,2O-epoxy-10hydroxy-70-methoxy-9-oxo-lO0- (2-pyridylcarbonyl) oxy-11taxen-13a-yl (2R,3S)-3 -tert-butoxycarbonylamino-2hydroxy-3-phenylpropionate are obtained in the form of a white foam, the characteristics of which are as follows:

- optical rotation: [a]₂₀ = -52 (c = 0.5; methanol).

- NMR spectrum (400 MHz: CDC1₃) ; chemical shifts δ in

AP/P/ 9 7 / 0 1 0 90

AP. Ο Ο 7 8 5 ρρ,; coupling constants J in Hz) : 1.31 (s, 3H: -CH₃ at postion 16 or 17); 1.37 [(s, 12H: -C(CH₃)₃ and -CH₃ at position 16 or 17]; 1.74 (s, 1H: -OH at position 1);

1.78 (s, 3H: -CH₃) ; 1.82 and 2.78 (2 mts, IH each: -CH₂5 at position 6); 1.97 (s, 3H: -CH₃) ; 2.35 (d, J = 9, 2H:

-CH₂- at position 14); 2.40 (s, 3H: -COCH₃) ? 3.40 (d, J = 4.5, IH: -OH at position 2'); 3.43 (s, 3H: -OCH₃) ;

3.92 (d, J = 7.5, IH: -Ξ at position 3); 3.98 (dd, J = and 7, IH: -H at position 7); 4.20 and 4.32 (2 d, J = 8.5, IH each: -CH₂- at position 20); 4.64 (mt, IH: -Ξ at position 2'); 5.00 (broad d, J = 10, IH: -H at position 5); 5.28 (broad d, J = 10, IH: -H at position 3'); 5.43 (d, J = 10, IH: -CONH-); 5.73 (d, J = 7.5,

IH: -H at position 2); 6.22 (broad t, J = 9, IH: -H at

13); 6.67 (s, IH: -H at position 10); from 7.25 to 7.45 (mt, 5H: -C₆H₅ at position 3'); 7.51 [(mt, 3H:

-OCOC₆H₅(-H at position 3 and H at position 5) and -OCOC₅H₄N(-H at position 5)]; 7.61 [(t, J = 7.5, IH: -OCOC_gH_s(-H at position 4)]; 7.88 [(split t, J = 8 and

1, IH: -OCOC₅H₄N(-H at position 4)]; 8.12 [ (d, J = 7.5,

2H: -OCOCgH₅(-H at position 2 and -H at position 6)]; 8.20 (broad d, J = 8, IH: -OCOC₅H₄N(-H at position 3)] ; 8.82 (broad dd J = 5 and 1, IH: -OCOC₅H₄N(-H at position 6)] .

6 0 I 0 / L 6 /d/dV

Working as in Example 1, but starting from

300 mg of 4a-acetoxy-2a-benzoyloxy-50,2O-epoxy-10,100dihydroxy-70-methoxy-9-oxo-ll-taxen-13a-yl (2R,4S,5R) 3-tert-butoxycarbonyl-2- (4-methoxyphenyl) -4-phenyl-1,3 AP. ο ο 7 8 5 oxazolidine-5-carboxylate, 230 mg of 4a-acetoxy-2abenzoy loxy-5/3,2 0 -epoxy-l/3-hydroxy-7/3-methoxy - 9-oxo-10/3(2-pyridylcarbonyl)oxy-11-taxen-13a-yl (2R,4S,5R)-3tert-butoxycarbonyl-2- (4-metboxyphenyl) -4-phenyl-l, 35 oxazolidine-5-carboxylate are obtained in the form of a white foam.

EXAMPLE 3

Working as in Example 1, but starting from 300 mg of 4a-acetoxy-2a-benzoyloxy-10/Scyclopentylcarbonyloxy-5/S,20-epoxy-l/S-hydroxy-7/Smethoxy-9-oxo-11-taxen-13a-yl (2R, 4S, 5R)-3-tertbutoxycarbonyl-2 - (4-methoxyphenyl) -4-phenyl-l,3 oxazolidine-5-carboxylate, 96 mg of 4a-acetoxy-2abenz oyloxy-10/5 - eye lopentylcarbonyloxy- 5/3, 2 0 - epoxy-1/5 hydroxy-7/S-methoxy-9-oxo-11-taxen-13a-yl (2R,3S) -3tert-butoxycarbonylamino-2-hydroxy-3-phenylpropionate are obtained in the form of a white foam, the characteristics, of which are as follows:

- optical rotation: [α]₂₀ = “θθ (^{c =} 0.5; methanol).

- ¹H NMR spectrum (400 MHz; CDC1₃; chemical shifts 6 in ppm; coupling constants J in Hz); 1.25 (s, 6H: -CH₃ at positions 16 and 17); 1.39 [s, 9H; -C(CH₃)₃]; from 1.55 to 1.80 and from 1.90 to 2.10 (2 mts, 4H each: -CH₂- of the cyclopentyl); 1.71 (s, IH: -OH at position 1); 1.75 (s, 3H: -CH₃) ; 1.82 and 2.75 (2 mts, IH each: -CH₂- at position 6); 1.93 (s, 3H: -CH₃) ; 2.33 (d, J = 9 Hz, 2H: -CH₂- at position 14); 2.39 (s, 3H: -COCH₃) ; 2.95 (mt, IH: =CH- of the cyclopentyl); 3.38 (s, 3H: -OCH₃) ; 3.40

AP/P/ 97/01090

AP. Ο Ο 7 8 5

-*· .

J (d, J = 5, 1H: -OH at position 2'); 3.88 (d, J = 7.5,

1H: -H at position 3); 3.91 (dd, J = 11 and 7.5, 1H: -H at position 7); 4.19 and 4.32 (2 d, J = 8.5, 1H each: -CH₂ at position 20); 4.65 (mt, 1H: -H at position 2');

4.98 (broad d, J = 10, 1H: -H at position 5); 5.28 (broad d, J = 10, 1H: -H at position 3'); 5.41 (d, J = 10, 1H: -CONH-); 5.68 (d, J = 7.5, 1H: -H at position 2); 6.21 (broad t, J = 9, 1H: -H at position 13); 6.45 (s, 1H: -H at position 10); from 7.25 to 7.45 (mt, 5H:

-C₆H₅ at position 3'); 7.51 [t, J = 7.5, 2H: -OCOC₆H₅ (-H at position 3 and H at position 5)]; 7.63 [t, J = 7.5, 1H: -OCOC₆H₅ (-H at position 4)]; 8.12 [d, J = 7.5, 2H: -OCOCgHg (-H at position 2 and -H at position 6)].

Working as in Example 1, but starting from

300 mg of 4a-acetcxy-2a-benzoyloxy-50_/2O-epoxy-10,lO0dihydroxy-70-methoxy-9-oxo-ll-taxen-13a-yl (2R, 4S, 5R) 3-tert-butoxycarbonyl-2- (4-methoxyphenyl) -4-phenyl-l, 3oxazolidine-5-carboxylate, 410 mg of 4o'-acetoxy-2a'benzoyloxy-100 - cyclopentylcarbonyloxy- 50, 2 0 - epoxy-1020 hydroxy-70-methoxy-9-oxo-11-taxen-13a-yl (2R,4S,5R)-3tert-butoxycarbonyl-2- (4-methoxyphenyl) -4-phenyl-l,3oxazolidine-5-carboxylate are obtained in the form of a white foam.

EXAMPLE 4

Working as in Example 1, but starting from

300 mg of 4a-acetoxy-2a-benzoyloxy-lO0-cyclopropylcarbonyloxy- 50, 2 0 - epoxy-10 -hydroxy- 7 0 -methoxy- 9 - oxo -11 taxen-13a-yl (2R, 4S,5R)-3-tert-butoxycarbonyl-2-(4AP/PZ 97 / 0 1 0 90

AP. Ο Ο 7 8 5 methoxyphenyl )-4 -phenyl -1,3 - oxazolidine - 5 - carboxylate, 130 mg of 4a-acetoxy-2a-benzoyloxy-10/3cyclopropylcarbonyloxy- 5/3, 2 0 - epoxy-l/S-hydroxy-7/3methoxy-9-oxo-ll-taxen-13a-yl (2R,3S)-3-tert5 butoxycarbonylamino-2-hydroxy-3-phenylpropionate are obtained in the form of a white foam, the characteristics of which are as follows:

- optical rotation: [a]₂₀ = “71 (c = 0.5; methanol).

- ¹H NMR spectrum (400 MHz; CDCl₃, chemical shifts δ in ppm; coupling constants J in Hz): 1.00 and 1.19 (2 mts,

2H each: -CH₂- of the cyclopropyl); 1.25 (s, 3H: -CH₃ at position 16 or 17); 1.27 (s, 3H: -CH₃ at position 16 or

17; 1.39 [s, 9H: -C(CH₃)₃1; 1.71 (s, IH: -OH at position 1); 1.75 (s, 3H: -CH₃) ; from 1.70 to 1.90 (mt, IH: =CH15 of the cyclopropyl); 1.82 and 2.75 (2 mts, IH each:

-CH₂- at position 6); 1.93 (s, 3H: -¾) ; 2.33 (d, J =

9, 2H: -CH₂- at position 14); 2.40 (s, 3H: -COCH₃) ; 3.35 (s, 3H: -OCH₃); 3.40 (d, J = 5, IH: -OH at position 2'); 3.88 (d, J = 7.5, IH: -H at position 3); 3.89 (dd,

J = 11 and 7.5, IH: -H at position 7); 4.19 and 4.32 (2d, J = 8.5, IH each: -CH₂- at position 20); 4.65 (mt, IH: -H at position 2'); 5.00 (broad d, J = 10, IH: -H at position 5); 5.28 (broad d, J = 10, IH: -H at position 3'); 5.42 (d, J = 10, IH: -C0NH-); 5.68 (d, J = 7.5, IH: -H at position 2); 6.21 (broad t, J = 9, IH:

-H at position 13); 6.48 (s, IH: -H at position 10); from 7.25 to 7.45 (mt, 5H: -C₆H₅ at position 3'); 7.52 [t, J = 7.5, 2H: -OCOC₆H₅ (-H at position 3 and H at

AP/P/ 97 / 0 1 0 98

AP. Ο Ο 7 8 5

		41
position	5)]; 7.64	[t, J = 7.5,	1H:	-OCOC₆H₅ (-H at
position	4)]; 8.12	[d, J = 7.5,	2H:	-OCOC_eH₅ (-H at

position 2 and -H at position 6)].

Working as in Example 1, but starting from

300 mg of 4a-acetoxy-2a-benzoyloxy-50,2O-epoxy-10,100dihydroxy-70-methoxy-9-oxo-ll-taxen-13a-yl (2R, 4S, 5R) 3-tert-butoxycarbonyl-2- (4-methoxyphenyl) -4-phenyl-l,3oxazolidine-5-carboxylate, 435 mg of 4a!-acetoxy-2aibenzoyloxy-lO0-cyclopropylcarbonyloxy-50, 2O-epoxy-10hydroxy-70-methoxy-9-oxo-ll-taxen-13a-yl (2R, 4S, 5R) -3tert-butoxycarbonyl-2- (4-methoxyphenyl) -4-phenyl-l,3 oxazolidine-5-carboxylate are obtained in the form of a white foam.

EXAMPLE 5

Working as in Example 1, but starting from

430 mg of 4a-acetoxy-2a-benzoyloxy-50,2O-epoxy-10hydr oxy - 7 0 - me thoxy -10 0 -me thoxyac e t oxy - 9 - oxo -11 - taxen 13a-yl (2R, 4S, 5R)-3-tert-butoxycarbonyl-2-(4methoxyphenyl) -4-phenyl-l, 3 - oxazolidine -5- carboxylate,

164 mg of 4a-acetoxy.-2oi-benzoyloxy-50,2O-epoxy-10hydr oxy - 7 0 - me thoxy -10 0 - me thoxyac e t oxy - 9 - oxo -11 -1 axen 13a-yl (2R,3S) -3-tert-butoxycarbonylamino-2-hydroxy-3phenylpropionate are obtained in the form of a white foam, the characteristics of which are as follows:

- optical rotation: [a]₂₀ = “48 (c = 0.5; methanol)

- ¹H NMR spectrum (300 MHz: CDC1₃; δ in ppm; coupling constants J in Hz): 1.17 (s, 3H: -H₃) ; 1.22 (s, 3H: -CH₃) ; 1.35 (s, 9H: -C(CH₃)₃; 1.75 (s, 3H: -CH₃) ; 1.80

AP/P/ 97 / 0 1 0 90

AP. Ο Ο 7 8 5 and 2.75 (2 mts, 1 H each: -CH₂- 6); 1.90 (s, 3H: -CH₃); 2.30 (d, J = 9, 2H: -CH₂- 14); 2.37 (s, 3H: -COCH₃) ;

3.35 and 3.55 (2 s, 3H each): -OCH₃) ; 3.40 (d, J = 5,

IH: -OH 2'); 3.85 (d, J = 7, IH: -H 3); 3.88 (dd, J =

11 and 7, IH: -H 7); 4.17 and 4.32 (2 d, J = 8.5, IH each: -CH₂- 20); 4.19 and 4.27 (2 d, J = 15, IH each: -OCOCH₂OCH₃) ; 4.65 (mt, IH: -H 2'); 4.97 (broad d, J = 10, IH: -H 5); 5.25 (broad d, J = 10, IH: -H 3'); 5.42

	(d, J = 10, IH:	-CONH-); 5.66 (d,	J = 7, IH: -H	2) ;
10	6.18 (broad t,	J = 9, IH: -H 13);	6.52 (s,	IH:	-H 10);
	from 7.30 to 7.	50 (mt, 5H: -CgH_s 3	'); 7.51	[ (t,	J = 7.5,
	2H: -OCOC₆H₅(-H	3 and H 5)]; 7.63	[(t, J =	7.5,	IH:

-OCOC₆H₅(-H 4)]; 8.12 (d, J = 7.5, 2H: -OCOC₆H₅(-H 2 and H 6) ] .

The new products of general formula (I) in which Z represents a radical of general formula (II) manifest significant inhibitory activity with respect ' to abnormal cell proliferation, and possess therapeutic properties permitting the treatment of patients having pathological conditions associated with abnormal cell proliferation. The pathological conditions include the abnormal cell proliferation of malignant or nonmalignant cells of various tissues and/or organs, comprising, without implied limitation, muscle, bone or connective tissue, the skin, brain, lungs, sex organs, the lymphatic or renal systems, mammary or blood cells, liver, the digestive system, pancreas and thyroid or adrenal glands. These pathological conditions can also

AP/P/ 97 / 0 1 0 90

AP. Ο ύ 7 8 5

include psoriasis, solid tumours, cancers of the ovary, breast, brain, prostate, colon, stomach, kidney or testicles, Kaposi's sarcoma, cholangiocarcinoma, choriocarcinoma, neuroblastoma, Wilms' tumour,

Hodgkin's disease, melanoma, multiple myeloma, chronic lymphocytic leukaemia and acute or chronic granulocytic lymphoma. The new products according to the invention are especially useful for the treatment of cancer of the ovary. The products according to the invention may be used to prevent or delay the appearance or reappearance of the pathological conditions, or to treat these pathological conditions.

The products according to the invention may be administered to a patient according to different dosage forms suited to the chosen administration route, which is preferably the parenteral route. Parenteral administration comprises intravenous, intraperitoneal,intramuscular or subcutaneous administration.

z

Intraperitoneal or intravenous administration is more especially preferred.

The present invention also comprises pharmaceutical compositions containing at least one product of general formula (I), in a sufficient amount suitable for use in human or veterinary therapy. The compositions may be prepared according to the customary methods, using one or more pharmaceutically acceptable adjuvants, vehicles or excipients. Suitable vehicles include diluents, sterile aqueous media and various

AP/P/ 97 / 0 1 0 90

AP. u u 7 8 5 non-toxic solvents. Preferably, the compositions take the form of aqueous solutions or suspensions, injectable solutions which can contain emulsifying agents, colourings, preservatives or stabilizers. However, the compositions can also take the form of tablets, pills, powders or granules which can be administered orally.

The choice of adjuvants or excipients may be determined by the solubility and the chemical properties of the product, the particular mode of administration and good pharmaceutical practice.

For parenteral administration, sterile, aqueous or non-aqueous solutions or suspensions are used. For the preparation of non-aqueous solutions or suspensions, natural vegetable oils such as olive oil, sesame oil or liquid petroleum, or injectable organic esters such as ethyl oleate, may be used. The sterile aqueous solutions can consist of a solution of a pharmaceutically acceptable salt dissolved in water.

The aqueous,. solutions are suitable for intravenous administration provided the pH is appropriately adjusted and the solution is made isotonic, for example with a sufficient amount of sodium chloride or glucose. The sterilization may be carried out by heating or by any other means which does not adversely affect the composition.

It is clearly understood that all the products participating in the compositions according to

AP/P/ 97 / 0 1 0 90 0'

AP.00785 the invention must be pure and non-toxic in the amounts used.

The compositions can contain at least 0.01% of therapeutically active product. The amount of active product in a composition is such that a suitable dosage can be prescribed. Preferably, the compositions are prepared in such a way that a single dose contains from 0.01 to 1000 mg approximately of active product for parenteral administration.

The therapeutic treatment may be performed concurrently with other therapeutic treatments including antineoplastic drugs, monoclonal antibodies, immunotherapy or radiotherapy or biological response modifiers. The response modifiers include, without implied limitation, lymphokines and cytokines such as interleukins, interferons (α, β or δ) and TNF. Other chemotherapeutic agents which are useful in the treatment of disorders due to abnormal cell proliferation include, without implied limitation, alkylating agents, for instance nitrogen mustards such as mechloretamine, cyclophosphamide, melphalan and chlorambucil, alkyl sulphonates such as busulfan, nitrosoureas such as carmustine, lomustine, semustine and streptozocin, triazenes such as dacarbazine, antimetabolites such as folic acid analogues, for instance methotrexate, pyrimidine analogues such as fluorouracil and cytarabine, purine analogues such as mereaptopurine and thioguanine, natural products, for

AP/P/ 9 7 / 0 1 0 90

AP.00785 instance vinca alkaloids such as vinblastine, vincristine and vindesine, epipodophyllotoxins such as etoposide and teniposide, antibiotics such as dactinomycin, daunorubicin, doxorubicin, bleomycin, plicamycin and mitomycin, enzymes such as Lasparaginase, various agents such as coordination complexes of platinum, for instance cisplatin, substituted ureas such as hydroxyurea, methylhydrazine derivatives such as procarbazine, adrenocortical suppressants such as mitotane and aminoglutethimide, hormones and antagonists such as adrenocorticosteroids such as prednisone, progestins such as hydroxyprogesterone caproate, methoxyprogesterone acetate and megestrol acetate, oestrogens such as diethylstilboestrol and ethynyloestradiol, antioestrogens such as tamoxifen, and androgens such as testosterone propionate and fluoxymesterone.

The doses used for carrying out the methods according to the invention are those which permit a prophylactic treatment or a maximum therapeutic response. The doses vary according to the administration form, the particular product selected and features distinctive to the subject to be treated. In general, the doses are those which are therapeutically effective for the treatment of disorders due to abnormal cell proliferation. The products according to the invention may be administered as often as necessary to obtain the desired therapeutic

AP/P/ 9 7 / 0 1 0 90

AP.00785 <*· effect. Some patients may respond rapidly to relatively high or low doses, and then require low or zero maintenance doses. Generally, low doses will be used at the beginning of the treatment and, if necessary, increasingly stronger doses will be administered until an optimum effect is obtained. For other patients, it may be necessary to administer maintenance doses 1 to 8 times a day, and preferably 1 to 4 times, according to the physiological requirements of the patient in question. It is also possible that some patients may require the use of only one to two daily administrations .

In man, the doses are generally between 0.01 and 200 mg/kg. For intraperitoneal administration, the doses will generally be between 0.1 and 100 mg/kg, preferably between 0.5 and 50 mg/kg and still more specifically between 1 and 10 mg/kg. For intravenous administration,^ the doses are generally between 0.1 and 50 mg/kg, preferably between 0.1 and 5 mg/kg and still more specifically between 1 and 2 mg/kg. It is understood that, in order to choose the most suitable dosage, account should be taken of the administration route, the patient's weight, general state of health and age and all factors which may influence the efficacy of the treatment.

The example which follows illustrates a composition according to the invention.

AP/P/ 9 7 / 0 1 0 9 0

AP.00785

EXAMPLE mg of the product obtained in Example 1 are dissolved in 1 cm³ of Emulphor EL 620 and 1 cm³ of ethanol, and the solution is then diluted by adding

18 cm³ of physiological saline.

The composition is administered by perfusion over 1 hour by introduction in physiological solution.

AP/P/ 9 7 / 0 1 0 9 0 , . ^nc’^w Particularly described and

u.u„a,„_ed mwour said invention and in

γ.η: manner (he same is to be performed ^{iAvc oeciar}- what l/we eiaim is -

Claims

1. New taxoids of general formula:

in which:

Z represents a hydrogen atom or a radical of 5 general formula:

R.NH 0

OH in which:

R_x represents a benzoyl radical optionally substituted with one or more identical or different atoms or radicals chosen from halogen atoms and alkyl

10 radicals containing 1 to 4 carbon atoms, alkoxy radicals containing 1 to 4 carbon atoms or trifluoromethyl radicals, a thenoyl or furoyl radical or a radical R₂-O-CO- in which R₂ represents:

- an alkyl radical containing 1 to 8 carbon atoms, an

15 alkenyl radical containing 2 to 8 carbon atoms, an alkynyl radical containing 3 to 8 carbon atoms, a cycloalkyl radical containing 3 to 6 carbon atoms, a cycloalkenyl radical containing 4 to 6 carbon atoms or

AP/P/ 9 7 / 0 1 0 90

AP.00785

-Ο

J

V,· _t j a bicycioalkyl radical containing 7 to 10 carbon atoms, these radicals being optionally substituted with one or more substituents chosen from halogen atoms and hydroxyl radicals, alkoxy radicals containing 1 to 4

5 carbon atoms, dialkylamino radicals in which each alkyl portion contains 1 to 4 carbon atoms, piperidino or morpholino radicals, 1-piperazinyl radicals (optionally substituted at position 4 with an alkyl radical containing 1 to 4 carbon atoms or with a phenylalkyl

10 radical in which the alkyl portion contains 1 to 4 carbon atoms), cycloalkyl radicals containing 3 to 6 carbon atoms, cycloalkenyl radicals containing 4 to 6 carbon atoms, phenyl radicals (optionally substituted with one or more atoms or radicals chosen from halogen

15 atoms and alkyl radicals containing 1 to 4 carbon atoms or alkoxy radicals containing 1 to 4 carbon atoms), cyano or carboxyl radicals or alkoxycarbonyl radicals in which the alkyl portion contains 1 to 4 carbon atoms,

20 - a phenyl or a- or β-naphthyl radical optionally substituted with one or more atoms or radicals chosen from halogen atoms and alkyl radicals containing 1 to 4 carbon atoms or alkoxy radicals containing 1 to 4 carbon atoms, or a 5-membered aromatic heterocyclic

25 radical preferably chosen from furyl and thienyl radicals, — or a saturated heterocyclic radical containing 4 to 6 carbon atoms, optionally substituted with one or more

AP/P/ 9 7 / 0 1 0 9 0

AP. Ο Ο 7 8 5 alkyl radicals containing 1 to 4 carbon atoms,

R₃ represents an unbranched or branched alkyl radical containing 1 to 8 carbon atoms, an unbranched or branched alkenyl radical containing 2 to 8 carbon

5 atoms, an unbranched or branched alkynyl radical containing 2 to 8 carbon atoms, a cycloalkyl radical containing 3 to 6 carbon atoms, a phenyl or a- or 0-naphthyl radical optionally substituted with one or more atoms or radicals chosen from halogen atoms and

10 alkyl, alkenyl, alkynyl, aryl, aralkyl, alkoxy, alkylthio, aryloxy, arylthio, hydroxyl, hydroxyalkyl, mercapto, formyl, acyl, acylamino, aroylamino, alkoxycarbonylamino, amino, alkylamino, dialkylamino, carboxyl, alkoxycarbonyl, carbamoyl, alkylcarbamoyl,

15 dialkylcarbamoyl, cyano, nitro and trifluoromethyl radicals, or a 5-membered aromatic heterocycle containing one or more identical or different hetero atoms chosen from nitrogen, oxygen and sulphur atoms and optionally substituted with one or more identical

20 or different substituents chosen from halogen atoms and alkyl, aryl, amino, alkylamino, dialkylamino, alkoxycarbonylamino, acyl, arylcarbonyl, cyano, carboxyl, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl or alkoxycarbonyl radicals, on the understanding that,

25 in the substituents of the phenyl, a- or 0-naphthyl and aromatic heterocyclic radicals, the alkyl radicals and the alkyl portions of the other radicals contain 1 to 4 carbon atoms, and that the alkenyl and alkynyl radicals

AP/P/ 9 7 / 0 1 0 9 0

AP. Ο Ο 7 β 5 contain 2 to 8 carbon atoms, and that the aryl radicals are phenyl or a- or /3-naphthyl radicals,

R₄ represents an alkanoyloxy radical in which the alkanoyl portion contains 2 to 6 carbon atoms in an

5 unbranched or branched chain, with the exception of an acetyl radical, an alkenoyloxy radical in which the alkenoyl portion contains 3 to 6 carbon atoms in an unbranched or branched chain or an alkynoyloxy radical in which the alkynoyl portion contains 3 to 6 carbon

10 atoms in an unbranched or branched chain, these radicals being optionally substituted with one or more halogen atoms or with an alkoxy radical containing 1 to 4 carbon atoms or an alkylthio radical containing 1 to 4 carbon atoms or with a carboxyl radical, an

15 alkyloxycarbonyl radical in which the alkyl portion contains 1 to 4 carbon atoms, a cyano or carbamoyl radical or an N-alkylcarbamoyl or N,N-dialkylcarbamoyl radical in which each alkyl portion contains 1 to 4 carbon atoms or, with the nitrogen atom to which it is

20 linked, forms a saturated 5- or 6-membered heterocyclic radical optionally containing a second hetero atom chosen from oxygen, sulphur or nitrogen atoms, optionally substituted with an alkyl radical containing 1 to 4 carbon atoms or a phenyl radical or a

25 phenylalkyl radical in which the alkyl portion contains 1 to 4 carbon atoms, or alternatively R₄ represents a cycloalkanoyloxy radical in which the cycloalkanoyl portion contains 4 to 8 carbon atoms or a

AP/P/ 9 7 / 0 1 0 90

AP. Ο Ο 7 8 5 cycloalkenoyloxy radical in which the cycloalkenoyl portion contains 4 to 8 carbon atoms, or alternatively R₄ represents a benzoyloxy radical or a heterocyclecarbonyloxy radical in which the heterocyclic portion

5 represents a 5- or 6-membered aromatic heterocycle containing one or more hetero atoms chosen from oxygen, sulphur or nitrogen atoms,

R_s represents an alkoxy radical containing 1 to 6 atoms this carbon in an unbranched or branched

10 chain, optionally substituted with an alkoxy radical containing 1 to 4 carbon atoms, an alkenyloxy radical containing 3 to 6 carbon atoms, an alkynyloxy radical containing 3 to 6 carbon atoms, a cycloalkyloxy radical containing 3 to 6 carbon atoms or a cycloalkenyloxy ¹5 radical containing 3 to 6 carbon atoms, these radicals being optionally substituted with one or more halogen atoms or with an alkoxy radical containing 1 to 4 carbon atoms, an alkylthio radical containing 1 to 4 carbon atoms or a carboxyl radical, an alkyloxycarbonyl

20 radical in which the alkyl portion contains 1 to 4 carbon atoms, a cyano or carbamoyl radical or an N-alkylcarbamoyl or Ν,Ν-dialkylcarbamoyl radical in which each alkyl portion contains 1 to 4 carbon atoms or, with the nitrogen atom to which it is linked, forms

25 a saturated 5- or 6-membered heterocyclic radical optionally containing a second hetero atom chosen from oxygen, sulphur or nitrogen atoms, optionally substituted with an alkyl radical containing 1 to 4

AP/P/ 97/01090

AP. Ο Ο 7 8 5 .,-/7¹

Ή carbon atoms or a phenyl radical or a phenylalkyl radical in which the alkyl portion contains 1 to 4 carbon atoms .

2. New taxoids according to claim 1 for

5 which Z represents a hydrogen atom or a radical of general formula (II) in which R_x represents a benzoyl radical or a radical R₂-O-CO- in which R₂ represents a tert-butyl radical and R₃ represents an alkyl radical containing 1 to 6 carbon atoms, an alkenyl radical

10 containing 2 to 6 carbon atoms, a cycloalkyl radical containing 3 to 6 carbon atoms, a phenyl radical optionally substituted with one or more identical or different atoms or radicals chosen from halogen atoms and alkyl, alkoxy, dialkylamino, acylamino,

15 alkoxycarbonylamino or trifluoromethyl radical, or a 2or 3-furyl, 2- or 3-thienyl or 2-, 4- or 5-thiazolyl radical, and R₄ represents an alkyloxyacetoxy radical ' in which the alkyl portion contains 1 to 4 carbon atoms, a cycloalkanoyloxy radical in which the

20 cycloalkanoyl portion contains 4 to 8 carbon atoms or a pyridylcarbonyloxy radical, and R₅ represents an unbranched or branched alkyloxy radical containing 1 to

6 carbon atoms .

3 . New taxoids according to claim 1 for

25 which Z represents a hydrogen atom or a radical of general formula (II) in which R_x represents .a benzoyl radical or a radical R₂-O-CO- in which R₂ represents a tert-butyl radical and R₃ represents an isobutyl,

AP/P/ 9 7 / 0 1 0 90

AP. Ο ΰ 7 8 5 isobutenyl, butenyl, cyclohexyl, phenyl, 2-furyl,

5 2-pyridylcarbonyloxy or 3-pyridylcarbonyloxy radical, and R₅ represents a methoxy radical.

4. Process for preparing the taxoids according to one of claims 1, 2 and 3 for which Z represents a radical of general formula (II) ,

10 characterized in that a product of general formula:

in which R₄ and R₅ are defined as in one of claims 1, 2 and 3, is esterified by means of an acid of general formula:

AP/P/ 97/01090 in which and R, are defined as above, and either R₆15 represents a hydrogen atom and R₇ represents a group protecting the hydroxyl function, or R_g and R₇ together form a saturated 5- or 6-membered heterocycle, or by means of a derivative of this acid, to obtain an ester

AP. Ο ο 7 8 5 of general formula:

in which R_1Z R₃, R₄, R₅, R_s and R₇ are defined as above, the protective groups of which, represented by R_?and/or R_s and R₇, are replaced by hydrogen atoms.

5. Process according to claim 4, characterized in that the esterification is performed by means of an acid of general formula (IV) in the presence of a condensing agent and an activating agent in an organic solvent at a temperature of between -10 and 90°C.

6. Process according to claim 4, characterized in that the esterification is performed by means of an acid of general formula (IV) in the form of the symmetrical anhydride, working in the presence of an activating agent in an organic solvent at a temperature of between 0 and 90°C.

7. Process according to claim 4, characterized in that the esterification is performed using the acid of general formula (IV) in halide form or in the form of a mixed anhydride with an aliphatic or aromatic acid, optionally prepared in situ, in the presence of a base, working in an organic solvent at a

AP/P/ 9 7 / 0 1 0 90

AP.00785 temperature of between 0 and 80°C.

8. Process according to claim 4, characterized in that the protective groups R_? and/or R_gand R₇ are replaced by hydrogen atoms, working,

5 depending on their nature, in the following manner:

1) when R_g represents a hydrogen atom and R₇ represents a group protecting the hydroxyl function, the protective groups are replaced by hydrogen atoms by means of an inorganic or organic acid used alone or

10 mixed, working in an organic solvent chosen from alcohols, ethers, esters, aliphatic hydrocarbons, halogenated aliphatic hydrocarbons, aromatic hydrocarbons or nitriles at a temperature of between -10 and 60°C,

15 2) when R_g and R_? together form a saturated 5- or 6membered heterocycle of general formula:

R₈ R^ (VI)

AP/P/ 97/01090 in which R_x is defined as above and R_g and R₉, which may be identical or different, represent a hydrogen atom or an alkyl radical containing 1 to 4 carbon atoms, or an

20 aralkyl radical in which the alkyl portion contains 1 to 4 carbon atoms and the aryl portion preferably represents a phenyl radical optionally substituted with one or more alkoxy radicals containing 1 to 4 carbon atoms, or an aryl radical preferably representing a

AP. Ο Ο 7 8 5 phenyl radical optionally substituted with one or more alkoxy radicals containing 1 to 4 carbon atoms, or alternatively R₈ represents an alkoxy radical containing 1 to 4 carbon atoms or a trihalomethyl

5 radical such as trichloromethyl or a phenyl radical substituted with a trihalomethyl radical such as trichloromethyl and R_g represents a hydrogen atom, or alternatively R₈ and R_g, together with the carbon atom to which they are linked, form a 4- to 7-membered ring,

10 the protective group formed by R₆ and R₇ is replaced by hydrogen atoms, working, depending on the meanings of R_x, R₈ and R_g, in the following manner:

a) when R_x represents a tert-butoxycarbonyl radical and R₈ and R₉, which may be identical or

15 different, represent an alkyl radical or an aralkyl or aryl radical, or alternatively R₈ represents a trihalomethyl radical or a phenyl radical substituted with a trihalomethyl radical and R_g represents a hydrogen atom, or alternatively R₈ and R_g together form

20 a 4- to 7-membered ring, the ester of general formula (V) is treated with an inorganic or organic acid, where appropriate in an organic solvent such as an alcohol, to obtain the product of general formula:

AP/P/ 97/01090

AP.00785 (VII) in which R₃, R₄ and R₅ are defined as above, which is acylated by means of benzoyl chloride in which the phenyl ring is optionally substituted or by means of thenoyl chloride, of furoyl chloride or of a product of

5 general formula:

R₂-O-CO-X (VIII) in which R₂ is defined as above and X represents a halogen atom or a residue -O-R₂ or -O-CO-O-R₂, to obtain a product of general formula (I) in which Z represents

1C a radical of general formula (II),

b) when R_x represents an optionally substituted benzoyl radical, a thenoyl or furoyl radical or a radical R₂O-CO- in which R₂ is defined as above, R₈ represents a hydrogen atom or an alkoxy

15 radical containing 1 to 4 carbon atoms or a phenyl radical substituted with one or more alkoxy radicals containing 1 to 4 carbon atoms and R_g represents a hydrogen atom, the protective group formed by R_s and R₇is replaced by hydrogen atoms, in the presence of an

2 0 inorganic or organic acid used alone or mixed in a stoichiometric or catalytic amount, working in an organic solvent chosen from alcohols, ethers, esters,

AP/P/ 9 7 / 0 1 0 9 0

AP.00785 aliphatic hydrocarbons, halogenated aliphatic hydrocarbons and aromatic hydrocarbons at a temperature of between -10 and 60°C.

9. Process for preparing a new taxoid according to one of claims 1, 2 and 3 for which Z represents a hydrogen atom, R₄ is defined as in one of claims 1, 2 and 3 and R₅ is defined as in one of claims 1, 2 and 3, characterized in that 10-deacetylbaccatin

III of formula:

'.j (IX)

Vi'

10 is treated with a silyl halide of general formula:

(R)₃-Si-Hal (X) in which the symbols R, which may be identical or different, represent an alkyl radical containing 1 to 4 carbon atoms, optionally substituted with a phenyl

15 radical, a cycioalkyl radical containing 3 to 6 carbon atoms or a phenyl radical, to obtain a product of general formula:

0 6 0 10/16 Zd/dV

AP. Ο Ο 7 8 5 (XI) in which R is defined as above, which is treated with a product of general formula:

R'4-Xi (XU) in which R'₄ is such that R'₄-O- is identical to R₄5 defined as in one of claims 1, 2 and 3 and X_x represents a halogen atom, to obtain a product of general formula:

(ΧΠΙ)

AP/P/ 9 7 / 0 1 0 9 0 in which R and R₄ are defined as above, the silyl protective groups of which are replaced by hydrogen atoms to obtain a product of general formula:

(XIV)

AP.00785 in which R₄ is defined as above, which is etherified selectively at position 7 by the action of a product of general formula:

R'₅-X₂ (XV) in which R^z5 is such that R'₅-O- is identical to R_sdefined as in one of claims 1, 2 and 3 and X₂represents a reactive ester residue or a halogen atom, to give the product of general formula (I) in which Z represents a hydrogen atom.

10. Process for preparing a product according to one of claims 1, 2 and 3 for which Z represents a radical of general formula (II), R₄ is defined as in one of claims 1, 2 and 3 and R_s is defined as in one of claims 1, 2 and 3, characterized in that a product of general formula:

(XVI)

0 6 0 I 0 / L 6 /d/dV in which R_x, R₃, Rg and R_? are defined as in one of claims 1, 2, 3 and 4, is treated by means of a product of general formula:

(R)₃Si-Hal (X) in which the symbols R, which may be identical or different, represent an alkyl radical containing 1 to 4 carbon atoms, optionally substituted with a phenyl

AP. Ο Ο 7 8 5 radical, or a cycloalkyl radical containing 3 to 6 carbon atoms or a phenyl radical, to obtain a product of general formula:

in which R, R^,, R₃, R_g and R₇ are defined as above, which is functionalized at.position 10 by means of a product of general formula:

R'₄-Xi (XU) in which R₄ is such that R'₄-O- is identical to R₄defined as in one of claims 1, 2 and 3 and Χ_χrepresents a halogen atom or a reactive ester residue, to give a product of general formula:

AP/P/ 97 / 0 1 0 9 0 (xvin) in which R, R₃, R₃, R₄, R_g and R₇ are defined as above, the silyl protective group of which is replaced by a hydrogen atom to give a product of general formula:

AP.00785 which, by the action of a product of general formula (XV) , yields the product of general formula (V) , the protective groups of which are replaced by hydrogen atoms to give a product of general formula (I) in which Z represents a radical of general formula (II) .

11. Process for preparing a product according to one of claims 1, 2 and 3, characterized in that activated Raney nickel, in the presence of an aliphatic alcohol containing 1 to 3 carbon atoms or an ether, is reacted with a product of general formula:

(XXI)

06 0 1 0 / 16 /d/dV in which R₄ is defined as in one of claims 1, 2 and 3 and R' and R, which may be identical or different, represent a hydrogen atom or an alkyl radical containing 1 to 6 carbon atoms, an alkenyl radical

65 containing 2 to 6 carbon atoms, an alkynyl radical containing 3 to 6 carbon atoms, a cycloalkyl radical containing 2 to 6 carbon atoms or a cycloalkenyl

radical containing 3 to 6 carbon atoms, optionally 5 substituted, or alternatively R' and R, together with the carbon atom to which they are linked, form a cycloalkyl radical containing 3 to 6 carbon atoms or a cycloalkenyl radical containing 4 to 6 carbon atoms, and Z_x represents a hydrogen atom or a radical of

10 general formula:

(XXII) in which R_x and R₃ are defined 3 and R₆ and R₇ are defined as product of general formula:

as in one of claims 1 to in claim 4, to obtain a (XXIII)

AP/P/ 97 / 0 1 0 90 followed, when Z_x represents a radical of general 15 formula (XXII), by replacement of the protective groups represented by R_g and/or R_g and R₇ by hydrogen atoms under the conditions of claim 8.

AP.00785

12. Preparation process according to claim 11, characterized in that it is carried out at a temperature of between -10 and 60°C.

13 . 4a-Acetoxy-2a-benzoyloxy-5/S, 2 0-epoxy-l/S5 hydroxy - 7 β -me thoxy -10 β -me thoxy ac e toxy - 9 - oxo -11 - taxen 13a-yl (2R,3S) -3-tert-butoxycarbonylamino-2-hydroxy-3phenylpropionate.

14. 4o!-Acetoxy-2a!-benzoyloxy-lj3-hydroxy5/8,20- epoxy - 7 /3 - methoxy -10/S-cycl opr opyl carbony loxy - 9 10 oxo-11-taxen-13a-yl (2R, 3S)-3-tert-butoxycarbonylamino2-hydroxy-3-phenylpropionate.

15. 4a-Acet0xy-2a-benzoyloxy-l/S-hydroxy5/3,2 0 - epoxy- 7/S-me thoxy-10/3 - cyclopentylcarbonyloxy- 9 oxo-11-taxen-13a-yl (2R,3S)-3 -tert-butoxycarbonylamino15 2-hydroxy-3-phenylpropionate.

16. 4a-Acetoxy-2Q!-benzoyloxy-l/3-hydroxy5/5, 20-epoxy-7/S-methoxy-10/3- (2-pyridyl) carbonyloxy-9-, oxo-11-taxen-13a-yl (2R/3S)-3-tert-butoxycarbonylamino2-hydroxy-3-phenylpropionate.

20

17. 4a-Acetoxy-2a-benzoyloxy-l/3-hydroxy5/3, 20-epoxy-7/S-methoxy-10/3- (3-pyridyl) carbonyloxy-9oxo-ll-taxen-13a-yl (2R,3S)-3-tert-butoxycarbonylamino2-hydroxy-3-phenylpropionate.

18. Pharmaceutical composition,

25 characterized in that it contains at least one product according to one of claims 1, 2 and 3 for which Z represents a radical of general formula (II), in combination with one or more pharmaceutically

0 6 0 I 0 / L 6 /d/dV ay

AP. 0 0 7 8 5 acceptable diluents or adjuvants and optionally one or more compatible and pharmacologically active compounds.

19. Pharmaceutical composition, characterized in that it contains at least the product

5 according to claim 13 in combination with one or more pharmaceutically acceptable diluents or adjuvants and optionally one or more compatible and pharmacologically active compounds.

20. Pharmaceutical composition,

10 characterized in that it contains at least the product according to claim 14 in combination with one or more pharmaceutically acceptable diluents or adjuvants and optionally one or more compatible and pharmacologically active compounds.

15

21. Pharmaceutical composition, characterized in that it contains at least the product according to claim 15 in combination with one or more pharmaceutically acceptable diluents or adjuvants and optionally one or more compatible and pharmacologically

20 active compounds.

22. Pharmaceutical composition, characterized in that it contains at least the product according to claim 16 in combination with one or more pharmaceutically acceptable diluents or adjuvants and

25 optionally one or more compatible and pharmacologically active compounds.

23. Pharmaceutical composition, characterized in that it contains at least the product

AP/P/ 9 7 / 0 1 0 90

AP.00785 according to claim 17 in combination with one or more pharmaceutically acceptable diluents or adjuvants and optionally one or more compatible and pharmacologically active compounds.